FDA Clinical Hold: 21 CFR 312.42 Process Guide

What an FDA Clinical Hold Is and Who Imposes It

In United States pharmaceutical development, clinical trials involving human subjects proceed under an Investigational New Drug (IND) application governed by 21 CFR Part 312. When the Food and Drug Administration identifies critical deficiencies or safety hazards in a proposed or active protocol, it exercises statutory authority under 21 CFR § 312.42 by issuing a clinical hold.

Under 21 CFR § 312.42(d), a clinical hold is issued or authorized by the Division Director of the FDA review division responsible for the IND. The order may be communicated by telephone or other rapid means, or in writing, and it identifies the studies affected and briefly states the basis for the hold.

Under 21 CFR § 312.42(c), unless clinical trial subjects are exposed to immediate and serious safety risks, FDA will attempt to discuss and satisfactorily resolve the deficiency with the sponsor before it issues a clinical hold order.

Types of Clinical Holds: Complete vs. Partial Holds

The scope of a clinical hold depends on the nature of the identified deficiency and the specific trial populations exposed to risk:

Hold Dimension	Complete Clinical Hold	Partial Clinical Hold
Regulatory Scope	Applies to all clinical investigations conducted under the entire IND dossier.	Applies only to a designated study, specific patient cohort, dosage tier, or protocol arm.
Impact on New Enrollment	No new subjects may be screened, recruited, or administered the investigational product.	New recruitment is halted exclusively for the affected protocol, dose cohort, or patient subpopulation.
Impact on Enrolled Patients	Active subjects must be discontinued from the investigational drug unless the FDA explicitly permits continued therapy for patient safety.	Patients in unaffected arms continue therapy; affected subjects may only continue if FDA grants explicit safety permission.
Authorization to Resume	Requires a comprehensive Complete Response resolving all issues across the IND, followed by formal FDA written clearance.	Requires resolving specific deficiencies cited for the affected arm or protocol, followed by formal FDA written clearance.

Regulatory Grounds for Imposing a Clinical Hold

The legal standards for imposing a hold are codified in 21 CFR § 312.42(b) and differ depending on the trial phase:

Phase 1 Clinical Investigations

Under 21 CFR § 312.42(b)(1), FDA may place a proposed or ongoing Phase 1 investigation on clinical hold on grounds that include the following:

• Unreasonable and significant risk: Clinical evidence, nonclinical toxicology, or formulation characteristics indicate that human subjects are or would be exposed to an unreasonable and significant risk of illness or injury.
• Unqualified investigators: Clinical investigators are not qualified by scientific training and experience to conduct the investigation.
• Investigator Brochure deficiencies: The Investigator Brochure (IB) is misleading, erroneous, or materially incomplete.
• Insufficient risk assessment data: The IND does not contain sufficient information required under § 312.23 to assess the risks to subjects.
• Improper gender exclusion: For investigational drugs targeting life-threatening diseases that affect both sexes, men or women of reproductive potential are excluded from eligibility solely due to reproductive or developmental toxicity risks without regulatory justification.

Phase 2 and Phase 3 Clinical Investigations

Under 21 CFR § 312.42(b)(2), Phase 2 and Phase 3 investigations can be placed on clinical hold for any of the Phase 1 grounds listed above, or if:

• Deficient trial design: The plan or protocol is clearly deficient in design to meet its stated objectives.

Clinical Hold Timeline and Procedural Phases

The progression of an FDA clinical hold follows a strict statutory schedule governed by 21 CFR § 312.42:

1. Informal deficiency discussion (Pre-Hold): Unless subjects face immediate and serious risk, FDA attempts to discuss and resolve the deficiency with the sponsor before issuing a hold order.
2. Oral hold notification (Day 0): If deficiencies persist, the Division Director issues or authorizes the clinical hold order by telephone, other rapid means, or in writing.
3. Written clinical hold letter (Within 30 Calendar Days): Under 21 CFR § 312.42(d), the FDA must provide the sponsor with a comprehensive written letter detailing the specific scientific, clinical, or CMC grounds for the hold within 30 calendar days of oral imposition.
4. Sponsor Complete Response submission: The sponsor corrects the cited deficiencies and submits a complete response to FDA, requesting in writing that the hold be removed.
5. FDA statutory review clock (30 Calendar Days): Under 21 CFR § 312.42(e), the FDA must respond in writing within 30 calendar days of receiving the sponsor’s complete response.
6. Determination letter: The FDA communicates in writing FDA’s decision on the complete response. A sponsor that disagrees with the reasons for the hold may request reconsideration under 21 CFR § 312.48.

The Complete Response and Lifting a Hold

Under 21 CFR § 312.42(e), a sponsor may resume or begin the investigation only after FDA notifies it that the hold has been removed. The sponsor addresses the deficiencies cited by FDA and submits a complete response requesting removal of the hold. Sponsors working within regulatory affairs in the pharmaceutical industry coordinate this submission with the amended protocol, investigator materials and data that the hold letter calls for.

Common Misunderstandings About Clinical Holds

• Assuming a trial restarts after 30 days: The 30-day period is FDA’s response time. Under 21 CFR § 312.42(e), the investigation may not proceed until FDA notifies the sponsor that the hold has been removed.
• Confusing the two 30-day periods: One is the written explanation FDA provides after imposing a hold (§ 312.42(d)); the other is FDA’s response to a sponsor’s complete response (§ 312.42(e)).
• Overlooking the one-year point: Under 21 CFR § 312.42(g), if all investigations under an IND remain on clinical hold for one year or more, FDA may place the IND on inactive status under 21 CFR § 312.45.

Related Regulatory Mechanisms

Clinical holds operate alongside other key FDA mechanisms across the pharmaceutical industry:

Regulatory Mechanism	Applicable Phase / Submission	Governing Regulation	Primary Agency Action
Clinical Hold	Investigational New Drug (IND) / Clinical Trials	21 CFR § 312.42	Suspends or delays trial execution and patient dosing due to safety or protocol design flaws.
Complete Response Letter (CRL)	New Drug Application (NDA) / BLA	21 CFR § 314.110	Refuses marketing approval for a commercial drug application until stated deficiencies are resolved (see the FDA NDA guide).

For related background, see the comparison of IND vs NDA, the guide to clinical trial protocol design, and the dictionary entry for ICH E1.

Frequently Asked Questions

What is the difference between a complete clinical hold and a partial clinical hold?

A complete clinical hold suspends all clinical investigations and dosing under the entire IND application. A partial clinical hold restricts only a specified protocol, dose cohort, or patient population, allowing unaffected portions of the trial program to continue recruitment and treatment.

How long does the FDA have to respond to a sponsor complete response?

Under 21 CFR § 312.42(e), FDA must respond in writing within 30 calendar days of receiving the sponsor’s complete response.

Can a sponsor resume a trial if the 30-day review period expires without an FDA response?

No. 21 CFR § 312.42(e) explicitly states that notwithstanding the 30-day response timeframe, an investigation may not proceed until the sponsor receives formal notification from the FDA that the hold has been removed.

What happens if an IND remains on clinical hold for more than one year?

Under 21 CFR § 312.42(g), if all investigations covered by an IND remain on clinical hold for one year or more, FDA may place the IND on inactive status under 21 CFR § 312.45.

Who can issue a clinical hold?

Under 21 CFR § 312.42(d), the hold is issued or authorized by the Division Director of the responsible FDA review division.

Can a sponsor appeal a clinical hold?

A sponsor that disagrees with the reasons for a hold can request reconsideration under 21 CFR § 312.48.

Sources

• US Food and Drug Administration / Government Publishing Office. “21 CFR § 312.42 Clinical holds and requests for modification.” Electronic Code of Federal Regulations, Title 21, Part 312: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-C/section-312.42 (checked 2026-11-07).
• Legal Information Institute, Cornell Law School. “21 CFR § 312.42”: https://www.law.cornell.edu/cfr/text/21/312.42 (checked 2026-11-07).